Tuhura Biosciences Inc HURA

$1.96 +0.03 (1.55%)

Valuation

Market cap
124,905,000
Revenue TTM
$0
Net income TTM
$-30,050,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.47

Trading

Volume
148,900
Avg volume
233,698
Day's range
$1.95 – $1.99
Shares out
63,727,000
Stochastic %K
34%
Beta
-0.21
Analysts
Strong Sell
Price target
$7.87

Price

Company profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 adminis...

Show more

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
813 875 6600
Website
https://www.tuhurabio.com
Address
10500 University Center Drive, Suite 110, Tampa, United States

Latest news

Stocktwits

toesinthesand Oct 9, 8:56 PM
$HURA why not?
0 replies
stocklord2026 Oct 6, 6:39 PM
$HURA DD soon
0 replies
CapitalWhale Oct 6, 3:42 AM
$HURA loading up the dip for the come back
0 replies
PastaSlobCFA Oct 5, 3:32 PM
$HURA bought more !!!
0 replies
HKLM93 Oct 5, 12:15 PM
$HURA why is this down after a big news
0 replies
Stock_Catcher Oct 5, 11:45 AM
$HURA TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
0 replies
TNNStockAnalysisNews Oct 5, 4:12 AM
Stocks Under $7 to Watch Tomorrow (Oct 5, 2026): $LUCD Down 27% on Zero News — and Analysts Are Still Saying Buy $URG A Uranium Miner Laying Out Its Growth Case $HURA An FDA Clearance Nobody’s Talking About Yet $CATX A Radiopharmaceutical Story With a 351% Analyst Gap $ZNTL A Major Catalyst Lands This Month https://truthsandnews.com/markets/top-stocks-under-7-to-watch-10-picks-for-oct-5
1 replies
Gemology Oct 2, 10:43 AM
$HURA If it fails, I’ll know soon enough
0 replies